Gastrointestinal Stromal Tumor GIST · Gastrointestinal Stromal Tumor GIST 25.07.2012 6...
Transcript of Gastrointestinal Stromal Tumor GIST · Gastrointestinal Stromal Tumor GIST 25.07.2012 6...
Gastrointestinal Stromal Tumor GIST
M. Regli
Universitätsklinik für Viszerale Medizin – Gastroenterologie
Gastrointestinal Stromal Tumor GIST 25.07.2012 2
Universitätsklinik für Viszerale Medizin – Gastroenterologie
(746 vs. 946 patients)
Gastrointestinal Stromal Tumor GIST 25.07.2012 3
Universitätsklinik für Viszerale Medizin – Gastroenterologie
GIST - Introduction
Epidemiology: • Incidence approx. 15 / 1'000'000 /y
• Prevalence 129 / 1'000'000
• 0.1 – 3% of all GI-malignoma
• mean age 50-70y
• Localization:
[Kindblom LG et al. Incidence, prevalence, phenotype and biologic spectrum of gastrointestinal stromal cell tumors (GIST) – A population-based study of 600 cases. Ann Oncol 2002;13(Suppl 5):157]
[Nilsson B et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era - a population-based study in western Sweden. Cancer 2005;103:821]
[Miettinen M et al. Gastrointestinal stromal tumors - definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001;438:1]
Gastrointestinal Stromal Tumor GIST 25.07.2012 4
Universitätsklinik für Viszerale Medizin – Gastroenterologie
Etiology - Pathogenesis
Originate from ICC (interstitial cells of Cajal)
pluripotent mesenchymal stem cells
smooth muscular and neuronal properties
autonomous pacemaker of intestinal contractions
[Hirota S et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577]
1998 gain-of-function Mutation of c-kit described
KIT 80-85% of GIST
PDGFRA 5-8% of GIST
uncontrolled activation of tyrosine kinase
uncontrolled growth / proliferation
Gastrointestinal Stromal Tumor GIST 25.07.2012 5
Universitätsklinik für Viszerale Medizin – Gastroenterologie
Molecular genetics – c-Kit-mutation analysis
c-Kit-Mutation1)
1) [Heinrich MC et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342] 2) [Tarn C et al. Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proc Natl Acad Sci U S A
2008;105:8387]
No known mutation: 'wild type' GIST, poor prognosis
IGF1R probably plays a role2)
Exon 9: poorer response to Imatinib, poorer prognosis
Exon 11: better response to Imatinib, better prognosis
Gastrointestinal Stromal Tumor GIST 25.07.2012 6
Universitätsklinik für Viszerale Medizin – Gastroenterologie
Clinical presentation
No symptoms 15 – 30%
Symptomatic GIST ~75%
[Mucciarini C et al. Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based study. BMC Cancer 2007;7:230]
Incidental findings e.g. on endoscopy, radiology, resections for other
reasons
GI bleeding 25 – 53% (overt bleeding 34%)
Abdominal pain 20 – 50%
Passage 10 – 30%: N/V, early satiety, ileus, pain
Palpable mass 8 – 13%
Gastrointestinal Stromal Tumor GIST 25.07.2012 7
Universitätsklinik für Viszerale Medizin – Gastroenterologie
Diagnostic workup
1) [Demetri GD et al. NCCN Clinical Practice Guidelines in Oncology. Soft Tissue Sarcoma V.2.2010. www.nccn.org] 2) [Demetri GD et al. NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors. J Natl Compr Canc Netw
2010;8:S-1]
Diagnostic modalities:
Endoscopy
Endosonography
Radiology (CT, PET-CT, MRI)
Histology / immunohistochemistry
EUS-guided biopsy / FNA (if feasible)
In some situations biopsy may not be necessary (ie classic EUS
findings, tumor easily resectable, preoperative therapy not required)2)
Is biopsy mandatory?
Diagnostic modality of choice: 1)
Gastrointestinal Stromal Tumor GIST 25.07.2012 8
Universitätsklinik für Viszerale Medizin – Gastroenterologie
Diagnostic workup
Endoscopy
• Drawback of Endoscopy w/ biopsy (stacked / bite-on-bite):
• Risk of bleeding / tumor perforation
• Poor diagnostic yield (17-42%) [Hunt GC et al. Yield of tissue sampling for submucosal lesions evaluated by EUS. Gastrointest Endosc 2003;57:68]
[Cantor MJ et al. Yield of tissue sampling for subepithelial lesions evaluated by EUS: a comparison between forceps biopsies and endoscopic submucosal resection. Gastrointest Endosc 2006;64:29]
• Endoscopic features of GIST:
Gastrointestinal Stromal Tumor GIST 25.07.2012 9
Universitätsklinik für Viszerale Medizin – Gastroenterologie
Diagnostic workup
EUS
• Classic EUS features of GIST:
• fourth wall layer (muscularis propria)
• round to oval shape
• hypoechoic
Gastrointestinal Stromal Tumor GIST 25.07.2012 10
Universitätsklinik für Viszerale Medizin – Gastroenterologie
Diagnostic workup
EUS +/- biopsy/FNA – Advantages:
• Tissue sampling
• Helps assessing malignant potential
• Sufficient specimen for cytologic diagnosis and immunohistochemistry
• Overall tissue yield of EUS-FNA in sampling subepithelial tumors: 91.8%
• Calculated sensitivity for diagnosis of GIST: 95%
[Ando N et al. The diagnosis of Gi stromal tumors with EUS-guided fine needle aspiration with immunohistochemical analysis. Gastrointest Endosc 2002;55:37]
• Diameter (ie >3-4cm)
• Echogenic foci
• Irregular borders
• Cystic spaces
• Lymph nodes
[Chak A et al. Endosonographic differentiation of benign and malignant stromal cell tumors. Gastrointest Endosc 1997;45:468]
≥ 2 criteria met: sensitivity 80-100%
≥ 1 criteria met: sensitivity 91%, specifity 88%,
PPV 83%
[Palazzo L et al. Endosonographic features predictive of benign and malignant gastrointestinal stromal cell tumours. Gut 2000;46:88]
Most accurate and reliable method to secure a diagnosis of GIST
Gastrointestinal Stromal Tumor GIST 25.07.2012 11
Universitätsklinik für Viszerale Medizin – Gastroenterologie
Diagnostic workup 18FDG-PET
• GIST highly metabolically active
• May not detect GIST <2cm
[Kamiyama Y et al. 18F-fluorodeoxyglucose positron emission tomography: useful technique for predicting malignant potential of gastrointestinal stromal tumors. World J Surg 2005;29:1429]
• Possible correlation between 18FDG-Uptake & mitotic index
• Monitoring tumor response to therapy:
predicting tumor response on imatinib therapy
- after 1mo in 85%
- after 3mo in 100%
[Stroobants S et al. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 2003;39:2012]
[Antoch G et al. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med 2004;45:357]
Gastrointestinal Stromal Tumor GIST 25.07.2012 12
Universitätsklinik für Viszerale Medizin – Gastroenterologie
Risk stratification
Normogram by Gold et al.3)
1) [Miettinen M et al. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum Pathol 2002;33:478] 2) [Lasota J, Miettinen M et al. KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs). Semin Diagn Pathol 2006;23:91]
‘Staging’
Risk stratification by mitotic index, size and site (‘Miettinen’)1,2)
3) [Gold JS et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol 2009;10:1045]
Gastrointestinal Stromal Tumor GIST 25.07.2012 13
Universitätsklinik für Viszerale Medizin – Gastroenterologie
Management localized GIST
- irregular border
- Cystic spaces
- Ulceration
- echogenic foci
- heterogenity
• Treatment strategies for localized GIST?
No large, prospective studies!
Optimal frequency not defined!
Low compliance for follow-up!
• Resection or serial follow-up
b) „after a thorough discussion with the
patient regarding the risks and benefits“
a) Possible high-risk EUS features:
* ESMO/NCCN; AGA >3cm *
Gastrointestinal Stromal Tumor GIST 25.07.2012 14
Universitätsklinik für Viszerale Medizin – Gastroenterologie
Management localized GIST
Principles of surgery?
1) [DeMatteo RP et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000;231:51]
• Complete tumor removal with clear resection margins
• Avoidance of tumor rupture
• Gastric GIST: lap. wedge resection when feasible
• Routine lymphadenectomy not necessary 1)
Gastrointestinal Stromal Tumor GIST 25.07.2012 15
Universitätsklinik für Viszerale Medizin – Gastroenterologie
Imatinib
[Demetri GD et al. NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors. J Natl Compr Canc Netw 2010;8:S-1]
Gastrointestinal Stromal Tumor GIST 25.07.2012 16
Universitätsklinik für Viszerale Medizin – Gastroenterologie
Imatinib
Settings / Indications?
1) [DeMatteo RP et al. Lancet 2009;373:1097], [Kang B et al. J Clin Oncol 2009;27(Suppl):abstract #e21515]
Adjuvant setting: effect of imatinib?
Neoadjuvant setting:
prolongs relapse-free survival RFS, overall survival not affected1)
At 1y RFS 98% vs. 83%, HR 0.35; best response for GIST >10cm with HR 0.28
dose / duration? 400mg qd at least 1y
High risk GIST: better RFS / OS with therapy 3y2)
2) [Joensuu H et al. Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO). J Clin Oncol 2011;29(Suppl): ASCO 2011, #LBA1]
Additive setting: incomplete resection (R1/2), intraoperative tumor
perforation
Primarily unresectable / marginally resectable
GIST (e.g. high operative risk for tumor bleeding or perforation)
Gastrointestinal Stromal Tumor GIST 25.07.2012 17
Universitätsklinik für Viszerale Medizin – Gastroenterologie
Follow up after complete resection
Modality?
Frequency?
[Demetri GD et al. NCCN Clinical Practice Guidelines in Oncology. Soft Tissue Sarcoma V.2.2010. www.nccn.org]
• History, physical exam
• CT scan (abdominal / pelvic)
• q3-6mo for 3-5y
• Then q1y
Gastrointestinal Stromal Tumor GIST 25.07.2012 18
Universitätsklinik für Viszerale Medizin – Gastroenterologie
Therapeutic algorithm
Gastrointestinal Stromal Tumor GIST 25.07.2012 19
Universitätsklinik für Viszerale Medizin – Gastroenterologie
Prognosis
Localized GIST: mean survival
Incomplete Resection or metastatic GIST: 5y-survival
mean survival
R0-Resected GIST: 5y-survival
5y overall
50-65%
<35%
<1y